This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
Density, Specific Gravity, and Overfill Volume of DARZALEX Containing Sorbitol1-3
|
|
|
|
|---|
DARZALEX (100 mg/5 mL)
| 1.022 at 20°C
| 1.0173 in normal saline
| 0.2-0.4
|
DARZALEX (400 mg/20 mL)
| 0.4-1.2
|
Literature Search
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 22 September 2026.
| 1 | Data on File. DARZALEX VIAL (100 AND 400 MG) 3.2.P.2.2.3 PHYSICOCHEMICAL AND BIOLOGICAL PROPERTIES - GEN 2; 2015. |
| 2 | Data on File. Janssen Scientific Affairs, LLC. Correspondence from Janssen Research and Development, LLC (Communication dated 23 May 2023); 2025. |
| 3 | Data on File. DARZALEX VIAL (100 AND 400 MG) 3.2.P.2.3 Manufacturing Process Development Control Strategy Development – In – Process Controls – Cilag VFL2 Gen 2; 2015. |